← Back to Screener
Ovid Therapeutics Inc. Common Stock (OVID)
Price$2.80
Favorite Metrics
Price vs S&P 500 (26W)70.70%
Price vs S&P 500 (4W)14.18%
Market Capitalization$363.97M
All Metrics
Book Value / Share (Quarterly)$1.00
P/TBV (Annual)0.89x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)69.09%
Cash Flow / Share (Quarterly)$-0.29
Price vs S&P 500 (YTD)66.68%
Net Profit Margin (TTM)-240.13%
EPS (TTM)$-0.26
10-Day Avg Trading Volume4.15M
EPS Excl Extra (TTM)$-0.26
Revenue Growth (5Y)-10.46%
EPS (Annual)$-0.24
ROI (Annual)-13.33%
Net Profit Margin (5Y Avg)-4365.33%
Cash / Share (Quarterly)$0.53
Revenue Growth QoQ (YoY)844.74%
ROA (Last FY)-11.54%
Revenue Growth TTM (YoY)1181.27%
EBITD / Share (TTM)$-0.26
ROE (5Y Avg)-16.86%
Operating Margin (TTM)-585.20%
Cash Flow / Share (Annual)$-0.29
P/B Ratio2.79x
P/B Ratio (Quarterly)0.89x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)48.38x
ROA (TTM)-18.63%
EV / EBITDA (TTM)2.82x
EPS Incl Extra (Annual)$-0.24
Current Ratio (Annual)8.97x
Quick Ratio (Quarterly)8.40x
3-Month Avg Trading Volume2.53M
52-Week Price Return861.67%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.00
P/S Ratio (Annual)50.19x
Asset Turnover (Annual)0.05x
52-Week High$3.10
Operating Margin (5Y Avg)-6058.75%
EPS Excl Extra (Annual)$-0.24
CapEx CAGR (5Y)-4.25%
Tangible BV CAGR (5Y)24.72%
26-Week Price Return74.68%
Quick Ratio (Annual)8.40x
13-Week Price Return71.43%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.97x
Enterprise Value$350.821
Revenue / Share Growth (5Y)-14.50%
Asset Turnover (TTM)0.08x
Book Value / Share Growth (5Y)8.63%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-240.13%
Cash / Share (Annual)$0.53
3-Month Return Std Dev87.52%
Net Income / Employee (TTM)$-1
ROE (Last FY)-13.33%
EPS Basic Excl Extra (Annual)$-0.24
Receivables Turnover (TTM)4168.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.26
ROI (TTM)-23.98%
P/S Ratio (TTM)50.19x
Pretax Margin (5Y Avg)-4365.20%
Revenue / Share (Annual)$0.10
Tangible BV / Share (Annual)$1.00
Price vs S&P 500 (52W)831.84%
Year-to-Date Return69.33%
5-Day Price Return-4.17%
EPS Normalized (Annual)$-0.24
ROA (5Y Avg)-9.66%
Net Profit Margin (Annual)-240.13%
Month-to-Date Return24.32%
Cash Flow / Share (TTM)$-0.68
EBITD / Share (Annual)$-0.23
Operating Margin (Annual)-585.20%
ROI (5Y Avg)-16.86%
EPS Basic Excl Extra (TTM)$-0.26
P/TBV (Quarterly)0.89x
P/B Ratio (Annual)0.89x
Pretax Margin (TTM)-240.13%
Book Value / Share (Annual)$1.00
Price vs S&P 500 (13W)70.74%
Beta0.18x
P/FCF (Annual)3.07x
Revenue / Share (TTM)$0.09
ROE (TTM)-23.98%
52-Week Low$0.26
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.38
4.38
4.38
4.35
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
OVIDOvid Therapeutics Inc. Common Stock | 50.19x | 1181.27% | — | — | $2.80 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Ovid Therapeutics is a biopharmaceutical company developing novel treatments for rare epilepsies and seizure-related neurological disorders. The company's pipeline features multiple programs with potential first-in-class and best-in-class mechanisms of action, targeting patient populations with limited treatment options.